Impact of GDUFA Performance Metrics on ANDA Approval Times
Tuesday, Sept. 23, 2014 • 1:30 p.m.- 3:00 p.m. EDT
Generic drugmakers: You have until OCT. 1 to be GDUFA-ready. Help is at hand. Read this NOW.
For generic drugmakers, Oct. 1 is Crunch Time — the date after which all your ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments (GDUFA) of 2012.
We’ve enlisted the assistance of Lachman Consulting’s Joan Janulis, a Hatch-Waxman pro and all-around expert on FDA regulation in the generic drug industry. She’ll help you read between the lines of the GDUFA performance metrics, associated guidance documents and MAPPs, and provide a roadmap to the post-GDUFA paradigm.
But make no mistake: this session is about much more than theory and abstraction. You’ll discover concrete examples that illustrate what ANDA sponsors can expect — and must prepare for.
In 90 fast-paced minutes, Ms. Janulis takes you from the big picture to nuts-and-bolts implementation. Here’s a point-by-point summary of what she’ll cover:
With time so short before GDUFA full implementation, every second of advance preparation pays off in faster drug approvals and fewer hassles. Don’t mess with the FDA … or your company’s well-being.